Humana (NYSE:HUM) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says

Humana (NYSE:HUM) had its price target boosted by research analysts at JPMorgan Chase & Co. from $214.00 to $316.00 in a note issued to investors on Monday,MarketScreener reports. The brokerage currently has a “neutral” rating on the insurance provider’s stock. JPMorgan Chase & Co.‘s target price would suggest a potential downside of 9.20% from the stock’s previous close.

Several other research analysts also recently weighed in on the stock. Barclays upped their target price on shares of Humana from $180.00 to $344.00 and gave the company an “equal weight” rating in a research note on Tuesday, May 26th. Royal Bank Of Canada reiterated a “sector perform” rating on shares of Humana in a report on Monday, June 1st. Evercore raised their target price on Humana from $195.00 to $250.00 in a research note on Thursday, April 30th. Wolfe Research raised Humana from a “hold” rating to a “strong-buy” rating in a research report on Thursday. Finally, Bank of America increased their price target on Humana from $267.00 to $340.00 and gave the company a “neutral” rating in a report on Thursday. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, fourteen have given a Hold rating and four have given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $286.13.

Humana Stock Down 0.6%

Shares of HUM traded down $2.06 during midday trading on Monday, reaching $348.02. 94,739 shares of the company were exchanged, compared to its average volume of 1,902,144. Humana has a 1-year low of $163.11 and a 1-year high of $351.88. The stock has a 50-day moving average price of $248.43 and a 200-day moving average price of $232.39. The company has a current ratio of 1.77, a quick ratio of 1.77 and a debt-to-equity ratio of 0.66. The company has a market cap of $41.78 billion, a price-to-earnings ratio of 37.18, a P/E/G ratio of 2.00 and a beta of 0.76.

Humana (NYSE:HUM) last posted its earnings results on Wednesday, April 29th. The insurance provider reported $10.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $9.97 by $0.34. The business had revenue of $39.65 billion during the quarter, compared to analyst estimates of $39.37 billion. Humana had a return on equity of 10.45% and a net margin of 0.82%.The company’s revenue for the quarter was up 23.5% compared to the same quarter last year. During the same quarter last year, the firm earned $11.58 earnings per share. Humana has set its FY 2026 guidance at 9.000- EPS. Research analysts expect that Humana will post 9 earnings per share for the current year.

Institutional Trading of Humana

A number of large investors have recently modified their holdings of the company. Vanguard Group Inc. lifted its position in Humana by 0.7% in the 4th quarter. Vanguard Group Inc. now owns 14,261,860 shares of the insurance provider’s stock valued at $3,652,890,000 after purchasing an additional 106,030 shares during the last quarter. Capital International Investors grew its position in Humana by 113.9% in the 4th quarter. Capital International Investors now owns 5,818,008 shares of the insurance provider’s stock worth $1,490,239,000 after purchasing an additional 3,097,571 shares during the last quarter. Pzena Investment Management LLC increased its stake in shares of Humana by 34.3% in the first quarter. Pzena Investment Management LLC now owns 5,470,982 shares of the insurance provider’s stock valued at $948,614,000 after purchasing an additional 1,398,774 shares during the period. State Street Corp raised its holdings in shares of Humana by 1.8% during the fourth quarter. State Street Corp now owns 5,462,549 shares of the insurance provider’s stock valued at $1,403,877,000 after buying an additional 97,211 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA raised its holdings in shares of Humana by 28.9% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 4,496,775 shares of the insurance provider’s stock valued at $1,151,759,000 after buying an additional 1,008,514 shares during the last quarter. Institutional investors and hedge funds own 92.38% of the company’s stock.

About Humana

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.